

Alexis Mathian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6058229/publications.pdf>

Version: 2024-02-01

114
papers

8,353
citations

53794

45
h-index

48315

88
g-index

119
all docs

119
docs citations

119
times ranked

13680
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis". <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e241-e241.	0.9	10
2	Response to: "Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on "Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al." by Notz et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e217-e217.	0.9	8
3	Response to: "Implications of SARS-CoV-2 infection for patients with rheumatic disease" by Lin et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e153-e153.	0.9	2
4	Response to "Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic" by Chuah et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e145-e145.	0.9	2
5	Response to: "Withdrawal of low-dose prednisone in inactive SLE patients: is there another alternative?" by Sabio. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e58-e58.	0.9	0
6	Response to: "Glucocorticoid withdrawal in lupus: to do or not to do?" by Acharya. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e45-e45.	0.9	0
7	Response to: "Comments on the article: "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial" by Mousavi and Taherifard. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e47-e47.	0.9	0
8	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 575-583.	0.9	61
9	Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. <i>British Journal of Haematology</i> , 2022, 196, 969-974.	2.5	85
10	Serum interferon- λ levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 901-903.	0.9	11
11	Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation. <i>Frontiers in Immunology</i> , 2022, 13, 790334.	4.8	10
12	Response to: "Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak" by Holubar et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e57-e57.	0.9	2
13	Response to: "Correspondence on "Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine" by Nikpour et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e34-e34.	0.9	29
14	Response to: "Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey" by Pliński et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e53-e53.	0.9	0
15	Response to: "Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus" by Kondo et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e78-e78.	0.9	0
16	Response to: "Presence of anti-phospholipid antibodies in COVID-19: a case series study" by Amezcua-Guerra et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e74-e74.	0.9	2
17	Response to: "COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine" by Teh et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e70-e70.	0.9	0
18	Response to: "Patients with lupus with COVID-19: University of Michigan experience" by Wallace et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e36-e36.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Response to: "Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India" by Goyal et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e72-e72.	0.9	0
20	Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1171-1174.	1.2	14
21	IgA dominates the early neutralizing antibody response to SARS-CoV-2. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	840
22	Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units. <i>Chest</i> , 2021, 159, 657-662.	0.8	78
23	Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration. <i>Kidney International Reports</i> , 2021, 6, 526-528.	0.8	8
24	TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1 β positive cancer-associated dermatomyositis. <i>Rheumatology</i> , 2021, 60, 5863-5867.	1.9	10
25	Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients. <i>European Journal of Cancer</i> , 2021, 149, 34-36.	2.8	5
26	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2098-2107.	2.9	47
27	Evolution of Nutritional Status after Early Nutritional Management in COVID-19 Hospitalized Patients. <i>Nutrients</i> , 2021, 13, 2276.	4.1	21
28	Clarkson's Disease Episode or Secondary Systemic Capillary Leak-Syndrome. <i>Chest</i> , 2021, 159, 441.	0.8	5
29	Response to: "Are patients with systemic lupus erythematosus at increased risk for COVID-19?" by Favalli et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e26-e26.	0.9	2
30	Azacitidine (AZA) for Patients with Vexas and Myelodysplastic Syndrome (MDS): Data from the French Vexas Registry. <i>Blood</i> , 2021, 138, 3689-3689.	1.4	2
31	Extracorporeal Membrane Oxygenation for Myositis-Associated Rapidly Progressive-Interstitial Lung Disease. <i>Chest</i> , 2021, 160, e680-e681.	0.8	0
32	Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1721-1729.	0.7	7
33	Handling shock in idiopathic systemic capillary leak syndrome (Clarkson's disease): less is more" comment. <i>Internal and Emergency Medicine</i> , 2020, 15, 347-348.	2.0	3
34	Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e148-e148.	0.9	8
35	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 197-197.	5.6	0
36	Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 339-346.	0.9	93

#	ARTICLE	IF	CITATIONS
37	Coronary artery disease in systemic lupus: A case-controlled angiographic study. <i>Autoimmunity Reviews</i> , 2020, 19, 102427.	5.8	5
38	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 1522-1531.	2.0	10
39	In-Hospital Mortality-Associated Factors in Patients With Thrombotic Antiphospholipid Syndrome Requiring ICU Admission. <i>Chest</i> , 2020, 157, 1158-1166.	0.8	12
40	Reducing lupus flares: should we be more careful about stopping glucocorticoids?. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 539-542.	3.0	3
41	Response. <i>Chest</i> , 2020, 158, 429-430.	0.8	0
42	Severe Viral Myopericarditis With Autoantibodies Directed Against RNA Polymerase III. <i>Annals of Internal Medicine</i> , 2020, 172, 502.	3.9	5
43	Prevalence and severity of malnutrition in hospitalized COVID-19 patients. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 214-219.	1.2	139
44	Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 837-839.	0.9	208
45	Systemic chloroquine intoxication: a hint from the peripheral blood smear. <i>American Journal of Hematology</i> , 2020, 95, 873-875.	4.1	2
46	COVID-19-associated collapsing glomerulopathy: a report of two cases and literature review. <i>Internal Medicine Journal</i> , 2020, 50, 1551-1558.	0.8	19
47	CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. <i>Journal of Autoimmunity</i> , 2019, 103, 102292.	6.5	7
48	Iron deficiency, an unusual cause of thrombocytopenia: results from a multicenter retrospective case-controlled study. <i>Annals of Hematology</i> , 2019, 98, 2299-2302.	1.8	8
49	Ultrasensitive serum interferon- γ quantification during SLE remission identifies patients at risk for relapse. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1669-1676.	0.9	59
50	Neurological Involvement in Childhood Evans Syndrome. <i>Journal of Clinical Immunology</i> , 2019, 39, 171-181.	3.8	6
51	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 81-88.	2.9	101
52	Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. <i>Journal of Neurology</i> , 2019, 266, 1073-1078.	3.6	18
53	Transvenous Renal Biopsy of Critically Ill Patients: Safety and Diagnostic Yield. <i>Critical Care Medicine</i> , 2019, 47, 386-392.	0.9	8
54	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1575-1585.e4.	2.9	86

#	ARTICLE	IF	CITATIONS
55	Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon- γ . <i>Arthritis and Rheumatology</i> , 2019, 71, 756-765.	5.6	51
56	Myocardial dysfunction is frequent in systemic capillary-leak syndrome (Clarkson disease) severe episodes. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1539-1540.	2.9	11
57	Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review. <i>Neuromuscular Disorders</i> , 2018, 28, 334-338.	0.6	3
58	Microbial ecology perturbation in human IgA deficiency. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	206
59	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212705.	0.9	38
60	Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 83-89.	3.4	57
61	Relapsing polychondritis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000788.	3.8	43
62	Lupus and vaccinations. <i>Current Opinion in Rheumatology</i> , 2018, 30, 465-470.	4.3	14
63	Renal effects of immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw382.	0.7	67
64	AA amyloidosis is an emerging cause of nephropathy in obese patients. <i>European Journal of Internal Medicine</i> , 2017, 39, e18-e20.	2.2	11
65	Panitumumab-Induced Immune Complex Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2017, 69, 320-321.	1.9	7
66	Long-term outcomes of refractory neurosarcoidosis treated with infliximab. <i>Journal of Neurology</i> , 2017, 264, 891-897.	3.6	90
67	Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 377-384.	5.8	49
68	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
69	Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. <i>Autoimmunity Reviews</i> , 2017, 16, 743-749.	5.8	101
70	Successful outcome of proliferative lupus nephritis during pregnancy: Toward a modern paradigm of lupus pregnancy?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 214, 201-203.	1.1	0
71	Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. <i>Journal of Neurology</i> , 2017, 264, 1218-1226.	3.6	23
72	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. <i>Nephrology Dialysis Transplantation</i> , 2017, 33, 1579-1590.	0.7	37

#	ARTICLE	IF	CITATIONS
73	Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. <i>PLoS ONE</i> , 2017, 12, e0183844.	2.5	174
74	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1009-1015.	0.9	112
75	Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 316-333.	3.3	79
76	Contact dermatitis due to ultrasound gel: A case report and published work review. <i>Journal of Dermatology</i> , 2016, 43, 318-320.	1.2	32
77	Atypical ocular manifestation of primary varicella zoster virus infection as the first manifestation of AIDS. <i>Aids</i> , 2016, 30, 674-676.	2.2	1
78	Ultraviolet light converts propranolol, a nonselective β -blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. <i>European Journal of Immunology</i> , 2015, 45, 3174-3187.	2.9	36
79	Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0143689.	2.5	37
80	The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1033-1042.	3.0	38
81	Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects. <i>Drugs</i> , 2015, 75, 835-846.	10.9	58
82	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2015, 14, 192-200.	5.8	118
83	Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. <i>Autoimmunity Reviews</i> , 2014, 13, 730-735.	5.8	79
84	Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 474-475.	0.9	12
85	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.	5.8	166
86	Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. <i>Clinical Rheumatology</i> , 2014, 33, 1209-1215.	2.2	41
87	Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. <i>Autoimmunity Reviews</i> , 2014, 13, 1082-1089.	5.8	106
88	Pathogenesis of relapsing polychondritis: A 2013 update. <i>Autoimmunity Reviews</i> , 2014, 13, 90-95.	5.8	110
89	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2013, 149, 935.	4.1	91
90	Primary Adrenal Insufficiency Due to Bilateral Adrenal Hemorrhage-Adrenal Infarction in the Antiphospholipid Syndrome: Long-Term Outcome of 16 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3179-3189.	3.6	72

#	ARTICLE	IF	CITATIONS
91	Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1227-1234.	0.9	90
92	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	5.8	71
93	Late-Onset Systemic Lupus Erythematosus. <i>Drugs and Aging</i> , 2012, 29, 181-189.	2.7	78
94	Pathogenesis of Takayasu's arteritis: A 2011 update. <i>Autoimmunity Reviews</i> , 2011, 11, 61-67.	5.8	223
95	Interferon- γ induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB-NZW)F1 mice but not in BALB/c mice. <i>European Journal of Immunology</i> , 2011, 41, 863-872.	2.9	58
96	Cluster analysis of arterial involvement in Takayasu arteritis reveals symmetric extension of the lesions in paired arterial beds. <i>Arthritis and Rheumatism</i> , 2011, 63, 1136-1140.	6.7	39
97	Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon- γ production in patients with active disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 1698-1706.	6.7	116
98	Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3502-3511.	6.7	42
99	IFN- γ and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18995-19000.	7.1	52
100	Mevalonate Kinase Deficiency: A Survey of 50 Patients. <i>Pediatrics</i> , 2011, 128, e152-e159.	2.1	195
101	Active immunisation of human interferon γ transgenic mice with a human interferon γ Kinoid induces antibodies that neutralise interferon γ in sera from patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1138-1143.	0.9	41
102	B Cell and BAFF Dependence of IFN- γ -Exaggerated Disease in Systemic Lupus Erythematosus-Prone NZM 2328 Mice. <i>Journal of Immunology</i> , 2011, 186, 4984-4993.	0.8	77
103	Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. <i>PLoS Pathogens</i> , 2011, 7, e1002328.	4.7	111
104	Acute posterior multifocal placoid pigment epitheliopathy as the initial manifestation of sarcoidosis. <i>Journal of Ophthalmic and Vision Research</i> , 2011, 6, 338-43.	1.0	7
105	Mediation of nonerosive arthritis in a mouse model of lupus by interferon- γ -stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1127-1137.	6.7	36
106	Successful Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock Due to the Catastrophic Antiphospholipid Syndrome. <i>Annals of Internal Medicine</i> , 2010, 153, 487.	3.9	8
107	IFN- γ kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5294-5299.	7.1	205
108	Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease. <i>Journal of Immunology</i> , 2009, 183, 6021-6029.	0.8	122

#	ARTICLE	IF	CITATIONS
109	Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor. <i>Immunity</i> , 2009, 30, 899-911.	14.3	1,955
110	FoxP3+ Regulatory T Cells Suppress Early Stages of Granuloma Formation but Have Little Impact on Sarcoidosis Lesions. <i>American Journal of Pathology</i> , 2009, 174, 497-508.	3.8	116
111	Systemic IFN γ drives kidney nephritis in B6.Sle123 mice. <i>European Journal of Immunology</i> , 2008, 38, 1948-1960.	2.9	89
112	Type-I interferons and systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2006, 5, 554-562.	5.8	51
113	IFN γ Induces Early Lethal Lupus in Preautoimmune (New Zealand Black \times New Zealand White)F1 but Not in BALB/c Mice. <i>Journal of Immunology</i> , 2005, 174, 2499-2506.	0.8	248
114	Pentoxifylline-induced aseptic meningitis in a patient with mixed connective tissue disease. <i>Neurology</i> , 2002, 59, 1468-1469.	1.1	20